Brasada Capital Management LP Has $4.80 Million Position in Solventum Co. (NYSE:SOLV)

Brasada Capital Management LP lifted its position in Solventum Co. (NYSE:SOLV - Free Report) by 680.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,246 shares of the company's stock after buying an additional 61,246 shares during the quarter. Brasada Capital Management LP's holdings in Solventum were worth $4,795,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SOLV. Modus Advisors LLC acquired a new stake in Solventum in the 4th quarter valued at about $25,000. Stonebridge Financial Group LLC acquired a new stake in shares of Solventum in the fourth quarter valued at approximately $26,000. Crews Bank & Trust bought a new position in shares of Solventum during the 4th quarter worth approximately $32,000. Synergy Asset Management LLC acquired a new position in shares of Solventum during the 4th quarter worth approximately $35,000. Finally, Spire Wealth Management bought a new stake in Solventum in the 4th quarter valued at $37,000.

Analysts Set New Price Targets

SOLV has been the subject of a number of research analyst reports. Morgan Stanley lifted their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. Piper Sandler upped their price target on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research note on Friday, February 28th. The Goldman Sachs Group increased their price target on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday, March 3rd. Bank of America boosted their price objective on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Wednesday, February 26th. Finally, Wells Fargo & Company increased their target price on Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $79.86.

Solventum Price Performance

Shares of NYSE SOLV traded down $1.39 during midday trading on Friday, reaching $66.14. The company's stock had a trading volume of 672,816 shares, compared to its average volume of 1,303,374. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a market cap of $11.44 billion and a P/E ratio of 24.05. The business's 50 day moving average price is $72.58 and its two-hundred day moving average price is $71.56. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.